What Rgenta Therapeutics does

Rgenta Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecules that modulate RNA splicing to eliminate disease-causing proteins. Founded in 2018 and headquartered in Woburn, Massachusetts, the company applies a proprietary discovery platform that analyzes over 500 terabytes of genomic data to identify high-efficacy RNA target sites and designs focused compound libraries to engage those targets through splicing regulation and nonsense-mediated decay.

The company's pipeline is led by RGT-61159, an oral small molecule that modulates splicing of the MYB transcription factor to suppress oncogenic MYB protein production, currently in Phase 1a/b clinical trials for adenoid cystic carcinoma (ACC) and colorectal cancer (CRC) following FDA Orphan Drug Designation in September 2025. The second disclosed candidate, RGT-0474060, is an oral PMS1 inhibitor in IND-enabling studies for Huntington's disease with clinical entry targeted for 2027. Beyond direct pipeline assets, Rgenta offers the RSwitch technology, a regulatable gene therapy control system that uses oral small molecules as a 'dimmer switch' for transgene expression in gene and cell therapy applications, which the company is actively positioning for partnership.

Revenue will be generated primarily through drug commercialization and licensing/royalty agreements with larger pharmaceutical partners following regulatory approval. The company has established strategic alliances with GSK (December 2024, neurodegeneration and RNA biology) and Lundbeck (up to $110 million preclinical neuroscience deal) as core commercial pathways, supplemented by research partnerships with the Leukemia & Lymphoma Society Therapy Acceleration Program, ACCRF, and FARA. Currently pre-revenue, Rgenta has raised approximately $106.9 million cumulatively from investors including AstraZeneca (via AZ-CICC), Boehringer Ingelheim Venture Fund, Lilly Asia Ventures, Vivo Capital, Matrix Partners China, and Highlight Capital.

Name

Rgenta Therapeutics

Legal name

Rgenta Therapeutics Inc.

Website

https://rgentatx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Rgenta Therapeutics is a clinical-stage biotechnology company developing orally bioavailable small molecules that modulate RNA splicing to eliminate disease-causing proteins, with lead asset RGT-61159 in Phase 1a/b trials for adenoid cystic carcinoma and colorectal cancer.

Ownership category

akta.pro rank

Product category

RNA-targeting therapeutics (small molecule pharmaceuticals)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market) (HLAAADAJ), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)

Keywords

• RNA-targeting therapeutics
• Small molecule drugs
• Oncology drug discovery
• CNS drug development
• Splice modulating medicines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biotechnology company, Rgenta is developing RNA-targeting small molecule therapeutics for oncology and CNS disorders. Revenue will be generated through drug commercialization upon regulatory approval, with potential licensing and partnership agreements with larger pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Rgenta Therapeutics develops oral small-molecule drugs that target and modulate disease-causing RNA, primarily through splicing regulation and nonsense-mediated decay, to eliminate pathogenic proteins. Its lead clinical asset, RGT-61159, modulates MYB RNA splicing for adenoid cystic carcinoma (ACC) and colorectal cancer (CRC), and its second program, RGT-0474060, targets PMS1 RNA for Huntington's disease. The company also offers RSwitch, a regulatable gene-expression control system for gene and cell therapy applications, as a partnership-licensed platform.

Product overview

Rgenta Therapeutics is a clinical-stage biotechnology company developing RNA-targeting oral small molecule therapeutics. The company operates a unified platform approach combining its proprietary RNA-targeting discovery platform with specialized compound libraries to modulate RNA splicing and gene expression. The core product portfolio includes RGT-61159 (an oral MYB splicing modulator currently in Phase 1a/b trials for ACC and CRC) and RGT-0474060 (an oral PMS1 inhibitor for Huntington's disease in IND-enabling studies). The company also offers the RSwitch Technology platform for regulatable gene and cell therapy control, which operates as a separate but complementary technology using the same small molecule RNA-modulation expertise.

Differentiator

Problem solved

Functional benefit

Products and services

• RGT-61159 An orally available small molecule that modulates RNA splicing of the transcription factor MYB to inhibit production of oncogenic MYB protein via nonsense-mediated decay; in Phase 1a/b clinical development for adenoid cystic carcinoma (ACC) and colorectal cancer (CRC) with FDA Orphan Drug Designation in ACC.
• RGT-0474060 An orally bioavailable small molecule designed to inhibit PMS1 RNA and protein expression to halt CAG-repeat expansion in repeat expansion diseases, with a lead indication in Huntington's disease; currently in IND-enabling studies with clinical trial entry targeted for 2027.
• RSwitch Technology A regulatable gene therapy switch that enables dose-dependent control of transgene expression using an oral small molecule, functioning as a 'dimmer switch' for gene and cell therapy applications; offered to partners developing gene and cell therapies across multiple therapeutic indications.

Quantifiable outcome

• Phase 1a/b trial ongoing for RGT-61159 in patients with advanced ACC and CRC
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• GSKcoreStrategic or Co-development Partner · 4 December 2024Strategic alliance to develop RNA-targeted small molecule splice modulators. GSK is pursuing a two-speed pipeline strategy combining broad early-stage partnerships with selective downstream acquisitions. Rgenta partnership addresses neurodegeneration and RNA biology target identification.
• Leukemia & Lymphoma SocietycoreStrategic or Co-development Partner · 30 January 2024Rgenta joined The Leukemia & Lymphoma Society Therapy Acceleration Program to support development of therapies for blood cancers including AML, MDS, and T-ALL.
• LundbeckcoreStrategic or Co-development PartnerPartnership for neuro portfolio development. Lundbeck partnered with Rgenta and paid up to $110M for a neuro pact, focusing on developing treatments for neurological disorders using Rgenta's RNA-targeting platform.
• FARA (Friedreich's Ataxia Research Alliance)minorStrategic or Co-development PartnerPartnership supporting Friedreich's Ataxia research and development using RSwitch technology.
• ACCRF (Adenoid Cystic Carcinoma Research Foundation)minorStrategic or Co-development PartnerResearch partnership supporting ACC cancer research and development of RGT-61159.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Arrakis Therapeutics: Direct peer developing oral small molecules that bind structured RNA elements (rSMs) to modulate RNA function — a closely aligned RNA-targeting small molecule approach to Rgenta's, with overlapping indications in oncology and rare diseases.
• Skyhawk Therapeutics: Direct peer using proprietary SkySTARTM platform to discover small molecule RNA splicing modulators, with major partnerships (e.g., Genentech, Vertex) and overlapping Rgenta-like focus on previously undruggable RNA targets in oncology and CNS.
• Ribometrix: Direct peer developing small molecule drugs that target RNA 3D structures to modulate protein expression, with a pipeline spanning oncology and neurological disease — closely analogous to Rgenta's mechanism and therapeutic focus.
• Accent Therapeutics: Direct peer developing small molecule therapies that target RNA-modifying proteins (RMPs) for oncology, with overlapping leadership alumni — several Rgenta senior team members previously led discovery at Accent.
• Expansion Therapeutics: Direct peer pursuing oral small molecule therapeutics for repeat expansion diseases including Huntington's disease, DM1, and Friedreich's ataxia — directly comparable to Rgenta's RGT-0474060 PMS1 program.
• Remix Therapeutics: Direct peer developing small molecule therapeutics that modulate RNA processing, including splicing — closely aligned mechanism with Rgenta's platform and overlapping oncology/neurology focus.
• H3 Biomedicine: Direct peer (Eisai subsidiary) developing precision oncology therapeutics based on RNA splicing and genomic alterations — shares Rgenta's splicing modulator approach with cancer-focused indication strategy.

Broad incumbents

• PTC Therapeutics: Broader incumbent with multiple approved RNA-targeted/splicing-modulator therapies (e.g., risdiplam) and a pipeline spanning rare disease and oncology. Larger, public, and more commercially mature than Rgenta, but directly comparable mechanism.
• Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) leader with multiple approved RNA-targeted therapies and broad CNS/rare disease pipeline — a comparable but larger RNA-targeting incumbent, though using oligonucleotide rather than small molecule chemistry.
• Alnylam Pharmaceuticals: Established siRNA therapeutics leader with multiple approved products and a broad rare disease pipeline — a larger incumbent in the broader RNA-targeting therapeutic category, though using a different modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rgenta-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rgenta Therapeutics